Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 4:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 3,408 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Inflammatory Clear all
Recruiting Phase 3 Interventional

Abatacept for the Treatment of Giant Cell Arteritis

NCT04474847
View directory record Official record
Conditions
Giant Cell Arteritis
Interventions
Abatacept, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
50 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
5
States / cities
Rochester, Minnesota • New York, New York • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 24, 2026, 4:35 AM EDT
Completed Phase 2 Interventional Results available

Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer

NCT00193206
View directory record Official record
Conditions
Breast Cancer
Interventions
Gemcitabine, Epirubicin, Albumin-bound Paclitaxel
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older · Female only
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
13
States / cities
Fort Myers, Florida • Jacksonville, Florida • Lakeland, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Oct 24, 2026, 4:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study of the Anti-Inflammatory Effects of Colgate Total® During an Experimental Gingivitis Model

NCT01799226
View directory record Official record
Conditions
Gingivitis
Interventions
Toothpaste without triclosan, Triclosan
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 40 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Oct 24, 2026, 4:35 AM EDT
Withdrawn Phase 2 Interventional

Can PRP Reduce Pro-Inflammatory Biomarkers Following ACL Injury

NCT03389685
View directory record Official record
Conditions
ACL - Anterior Cruciate Ligament Rupture, ACL Injury
Interventions
Platelet Rich Plasma, Saline Placebo
Biological · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 15, 2024 · Synced Oct 24, 2026, 4:35 AM EDT
Terminated Phase 2Phase 3 Interventional

Study of Visilizumab Versus Placebo in Subjects With Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study

NCT00279435
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
visilizumab
Drug
Lead sponsor
Facet Biotech
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
9
States / cities
Atlanta, Georgia • Louisville, Kentucky • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2012 · Synced Oct 24, 2026, 4:35 AM EDT
Completed Phase 3 Interventional Results available

Human Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects With Moderate to Severe Crohn's Disease (ACCESS)

NCT00427921
View directory record Official record
Conditions
Crohn's Disease
Interventions
adalimumab
Biological
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Abbott Park, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 20, 2009 · Synced Oct 24, 2026, 4:35 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Characterizing Inflammatory Profiles and Suicidal Behavior in Adolescents

NCT04783506
View directory record Official record
Conditions
Suicide and Depression
Interventions
Observational Study
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
12 Years to 18 Years
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 24, 2026, 4:35 AM EDT
Completed Not applicable Interventional Results available

Multi-Center Comparative Trial of the ASR™-XL Acetabular Cup System vs. the Pinnacle™ Metal- on- Metal Total Hip System

NCT00561600
View directory record Official record
Conditions
Non-inflammatory Degenerative Joint Disease
Interventions
ASR™-XL Modular Acetabular Cup System, Pinnacle™ acetabular shell
Device
Lead sponsor
DePuy Orthopaedics
Industry
Eligibility
20 Years to 75 Years
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
8
States / cities
Rancho Mirage, California • Cumming, Georgia • Morton Grove, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Oct 24, 2026, 4:35 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Effects of Immulina TM Supplements With PASC Patients

NCT05524532
View directory record Official record
Conditions
Post Acute COVID-19 Syndrome
Interventions
Immulina TM, Placebo
Drug · Dietary Supplement
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
8
States / cities
Honolulu, Hawaii • Baton Rouge, Louisiana • New Orleans, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 24, 2026, 4:35 AM EDT
Completed Not applicable Interventional

Chronic Alcohol, Stress Inflammatory Response and Relapse Risk

NCT02193204
View directory record Official record
Conditions
Alcohol Dependence, Depressive Symptomatology
Interventions
Personal Stress Imagery, Neutral Imagery
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 50 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 6, 2020 · Synced Oct 24, 2026, 4:35 AM EDT
Terminated Not applicable Interventional Results available

S.A.F.E.BT System Extracorporeal Treatment With DIAPACT CRRT

NCT01312675
View directory record Official record
Conditions
Severe Sepsis
Interventions
S.A.F.E.BT
Device
Lead sponsor
B. Braun Medical Inc.
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Lexington, Kentucky • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 12, 2018 · Synced Oct 24, 2026, 4:35 AM EDT
Completed Phase 2 Interventional Results available

Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2)-Overexpressing Inflammatory Breast Cancer

NCT01325428
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Afatinib once daily (OD), Vinorelbine Weekly
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Los Angeles, California • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 19, 2016 · Synced Oct 24, 2026, 4:35 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Abatacept for SLE Arthritis (IM101-330)

NCT02429934
View directory record Official record
Conditions
Systemic Lupus Erythematosus Arthritis
Interventions
abatacept also known as Orencia also known as CTLA4-Ig, Placebo
Biological · Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Los Angeles, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 24, 2026, 4:35 AM EDT
Completed Phase 4 Interventional Results available

Infliximab for the Prevention of Recurrent Crohn's Disease After Surgery

NCT00688636
View directory record Official record
Conditions
Crohn's Disease
Interventions
infliximab, placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 72 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 26, 2016 · Synced Oct 24, 2026, 4:35 AM EDT
Completed Phase 1 Interventional

Biological Therapy in Treating Patients With Metastatic Cancer

NCT00004604
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Head and Neck Cancer, Liver Cancer, Lung Cancer, Metastatic Cancer, Ovarian Cancer, Pancreatic Cancer, Testicular Germ Cell Tumor
Interventions
CEA RNA-pulsed DC cancer vaccine
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 22, 2013 · Synced Oct 24, 2026, 4:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Vascular Inflammation and Anti-inflammatory Supplements After Adverse Pregnancy Outcomes

NCT04633551
View directory record Official record
Conditions
Pre-Eclampsia, Pre-Term, Intrauterine Growth Restriction, Hypertension in Pregnancy
Interventions
Anti-inflammatory supplement
Dietary Supplement
Lead sponsor
University of South Carolina
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 24, 2026, 4:35 AM EDT
Recruiting Not applicable Interventional

Remote Temperature Monitoring of Patients At Risk for Developing Fever

NCT06752512
View directory record Official record
Conditions
Fever, Cancer, Remote Patient Monitoring
Interventions
Remote Patient Monitoring
Device
Lead sponsor
AION Biosystems
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Schenectady, New York
Source: ClinicalTrials.gov public record
Updated Dec 30, 2024 · Synced Oct 24, 2026, 4:35 AM EDT
Recruiting Phase 2 Interventional

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

NCT07138898
View directory record Official record
Conditions
Rheumatic Disease
Interventions
Methotrexate, Sulfasalazine, Hydroxychloroquine, Leflunomide, Azathioprine, Mycophenolate, Cyclosporine, Tacrolimus, Etanercept, Adalimumab, Golimumab, Certolizumab, Infliximab, Rituximab, Belimumab, Tocilizumab, Anakinra, Canakinumab, Abatacept, Secukinumab, Ixekizumab, Bimekizumab, Ustekinumab, Guselkumab, Risankizumab, Tofacitinib, Upadacitinib
Drug · Biological
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 24, 2026, 4:35 AM EDT
Not listed No phase listed Observational

The PRECIOUS Study: Predicting Crohn's & ColitIs Outcomes in the United States

NCT03952364
View directory record Official record
Conditions
Crohn Disease, Ulcerative Colitis, IBD, Inflammatory Bowel Diseases
Interventions
PredictSURE IBD™
Other
Lead sponsor
PredictImmune Ltd
Industry
Eligibility
16 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
8
States / cities
Miami, Florida • St Louis, Missouri • New Brunswick, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 24, 2026, 4:35 AM EDT
Completed Not applicable Interventional

Effect of Automated Real-time Feedback on Early Sepsis Care

NCT05625464
View directory record Official record
Conditions
Sepsis
Interventions
SCTP
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
3,269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 23, 2022 · Synced Oct 24, 2026, 4:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Intestinal Ultrasound for the Evaluation of Pouchitis and Other Outcomes After Ileal Pouch-Anal Anastomosis

NCT06316999
View directory record Official record
Conditions
Ulcerative Colitis, Pouchitis
Interventions
Intestinal Ultrasound
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 24, 2026, 4:35 AM EDT
Recruiting Early Phase 1 Interventional

Repurposing Dupilumab for Management of Pruritic Genetic Inflammatory Skin Disorders

NCT05649098
View directory record Official record
Conditions
Skin Diseases
Interventions
Dupilumab
Drug
Lead sponsor
Northwestern University
Other
Eligibility
6 Months and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 24, 2026, 4:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Meloxicam Tablets Under Fasting Conditions

NCT00618163
View directory record Official record
Conditions
Inflammation
Interventions
Meloxicam
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 24, 2026, 4:35 AM EDT
Not listed Not applicable Interventional

Protocol-driven Hemodynamic Support for Patients With Septic Shock

NCT00335907
View directory record Official record
Conditions
Shock, Septic, Severe Sepsis, Sepsis
Interventions
Fluid and Vasopressor Protocol
Procedure
Lead sponsor
National Institute of General Medical Sciences (NIGMS)
NIH
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 25, 2010 · Synced Oct 24, 2026, 4:35 AM EDT